These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 32001263)

  • 1. Coding SNPs in hsa-miR-1343-3p and hsa-miR-6783-3p target sites of CYP2C19 modulates clopidogrel response in individuals with cardiovascular diseases.
    Sharma AR; Vohra M; Shukla V; Guddattu V; Razak Uk A; Shetty R; Umakanth S; Satyamoorthy K; Rai PS
    Life Sci; 2020 Mar; 245():117364. PubMed ID: 32001263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA hsa-miR-29a-3p modulates CYP2C19 in human liver cells.
    Yu D; Green B; Tolleson WH; Jin Y; Mei N; Guo Y; Deng H; Pogribny I; Ning B
    Biochem Pharmacol; 2015 Nov; 98(1):215-23. PubMed ID: 26296572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The correlation between platelet responsiveness to clopidogrel and CYP2C19 polymorphism in patients with peripheral vascular disease.
    El-Khodary NM; El-Behery AM; El-Askary NA; Donia HM; Omran GA
    Eur Rev Med Pharmacol Sci; 2021 Oct; 25(19):6065-6076. PubMed ID: 34661267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction between platelet-derived microRNAs and CYP2C19*2 genotype on clopidogrel antiplatelet responsiveness in patients with ACS.
    Peng L; Liu J; Qin L; Liu J; Xi S; Lu C; Yin T
    Thromb Res; 2017 Sep; 157():97-102. PubMed ID: 28734158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A GDF15 3' UTR variant, rs1054564, results in allele-specific translational repression of GDF15 by hsa-miR-1233-3p.
    Teng MS; Hsu LA; Juan SH; Lin WC; Lee MC; Su CW; Wu S; Ko YL
    PLoS One; 2017; 12(8):e0183187. PubMed ID: 28806401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of CYP2C19 genetic polymorphism on clopidogrel response in patients with ischemic stroke from Saudi Arabia.
    Alhazzani AA; Munisamy M; Karunakaran G
    Neurosciences (Riyadh); 2017 Jan; 22(1):31-37. PubMed ID: 28064328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of CYP2C19*2 polymorphism with clopidogrel resistance among patients with high cardiovascular risk in Northeastern Mexico.
    Cedillo-Salazar FR; Martínez-Jacobo L; Pérez-Páramo YX; Cerda-Flores R; Martínez LE; Jaime-Pérez JC; Moreno-Treviño MG; Pérez-Rodríguez E; Bosques-Padilla FJ; Cedillo-Avila M; Cedillo-Avila MA; Zamudio-Osuna M
    Arch Cardiol Mex; 2019; 89(4):324-329. PubMed ID: 31834317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
    Lin J; Han Z; Wang C; Yi X; Chai Z; Zhou Q; Huang R
    Eur J Clin Pharmacol; 2018 Sep; 74(9):1131-1140. PubMed ID: 29804161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of
    Liu YL; Hu XL; Song PY; Li H; Li MP; Du YX; Li MY; Ma QL; Peng LM; Song MY; Chen XP
    J Am Heart Assoc; 2021 Nov; 10(21):e021129. PubMed ID: 34713722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke.
    Yi X; Lin J; Wang Y; Zhou Q; Wang C; Cheng W; Chi L
    J Atheroscler Thromb; 2016 Oct; 23(10):1188-1200. PubMed ID: 26961113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increase in the risk of clopidogrel resistance and consequent TIMI flow impairment by DNA hypomethylation of CYP2C19 gene in STEMI patients undergoing primary percutaneous coronary intervention (PPCI).
    Sukmawan R; Hoetama E; Suridanda Danny S; Giantini A; Listiyaningsih E; Gilang Rejeki V; Aziz Alkatiri A; Firdaus I
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00738. PubMed ID: 33641235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of CYP2C19 Polymorphism with Clopidogrel Resistance in Patients with Acute Coronary Syndrome in China.
    Su Q; Li J; Tang Z; Yang S; Xing G; Liu T; Peng H
    Med Sci Monit; 2019 Sep; 25():7138-7148. PubMed ID: 31543510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy.
    Wu Y; Zhou Y; Pan Y; Zhao X; Liu L; Wang D; Wang C; Li H; Johnston SC; Meng X; Wang Y; Wang Y;
    Pharmacogenomics J; 2018 Dec; 18(6):713-720. PubMed ID: 29520080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MirSNPs in clopidogrel metabolism genes predict cardiovascular disease risk: a case-control study and meta-analysis.
    Sharma AR; Patagi S; Uk AR; Shetty R; Umakanth S; Satyamoorthy K; Rai PS
    Pharmacogenomics; 2021 Jan; 22(2):99-113. PubMed ID: 33356544
    [No Abstract]   [Full Text] [Related]  

  • 15. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.
    Namazi S; Kojuri J; Khalili A; Azarpira N
    Biochem Pharmacol; 2012 Apr; 83(7):903-8. PubMed ID: 22265638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.
    Gladding P; Webster M; Zeng I; Farrell H; Stewart J; Ruygrok P; Ormiston J; El-Jack S; Armstrong G; Kay P; Scott D; Gunes A; Dahl ML
    JACC Cardiovasc Interv; 2008 Dec; 1(6):620-7. PubMed ID: 19463375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study.
    Saydam F; Değirmenci İ; Birdane A; Özdemir M; Ulus T; Özbayer C; Çolak E; Ata N; Güneş HV
    Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):29-36. PubMed ID: 28135763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel.
    Pedersen RS; Nielsen F; Stage TB; Vinholt PJ; el Achwah AB; Damkier P; Brosen K
    Clin Exp Pharmacol Physiol; 2014 Nov; 41(11):870-8. PubMed ID: 25115434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.
    Karaźniewicz-Łada M; Danielak D; Rubiś B; Burchardt P; Oszkinis G; Główka F
    J Clin Pharmacol; 2014 Aug; 54(8):874-80. PubMed ID: 24782221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population.
    Guo YM; Zhao ZC; Zhang L; Li HZ; Li Z; Sun HL
    Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27323099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.